Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,335 | 215 | 1,112 |
| Samples | 387 | 75 | 309 |
| Peptides | 330 | 51 | 286 |
Function
IL12RB2 · Interleukin 12 receptor subunit beta 2
The protein encoded by this gene is a type I transmembrane protein identified as a subunit of the interleukin 12 receptor complex. The coexpression of this and IL12RB1 proteins was shown to lead to the formation of high-affinity IL12 binding sites and reconstitution of IL12 dependent signaling. The expression of this gene is up-regulated by interferon gamma in Th1 cells, and plays a role in Th1 cell differentiation. The up-regulation of this gene is found to be associated with a number of infectious diseases, such as Crohn's disease and leprosy, which is thought to contribute to the inflammatory response and host defense. Several transcript variants encoding different isoforms and non-protein coding transcripts have been found for this gene. [provided by RefSeq, Apr 2012].
Isoforms & Proteins
6 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 305 amino-acid changes on canonical ENST00000262345 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in IL12RB2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in IL12RB2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Cell Non-Hodgkins Lymphoma | 2/26 8% | 0/0 0% |
| Acute Myeloid Leukemia | 3/90 3% | 0/0 0% |
| Glioblastoma | 3/98 3% | 0/0 0% |
| Endometrial Carcinoma | 2/42 5% | 18/612 3% |
| Colorectal Carcinoma | 15/143 10% | 48/3239 1% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Melanoma | 4/210 2% | 31/1899 2% |
| Non-Small Cell Lung Carcinoma | 11/304 4% | 17/1390 1% |
| Squamous Cell Lung Carcinoma | 5/57 9% | 8/810 1% |
| Hodgkins Lymphoma | 2/16 12% | 0/122 0% |
| Gastric Carcinoma | 0/74 0% | 26/1809 1% |
| Ovarian Carcinoma | 4/109 4% | 11/998 1% |
| Other Solid Cancers | 3/94 3% | 18/1515 1% |
| Neuroendocrine Tumour | 4/154 3% | 4/577 1% |
| Bladder Carcinoma | 0/58 0% | 11/956 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 8/752 1% |
| Germ Cell Tumour | 0/25 0% | 2/169 1% |
| Cervical Carcinoma | 1/35 3% | 3/422 1% |
| Esophageal Carcinoma | 0/23 0% | 6/769 1% |
| Glioma | 0/52 0% | 15/2127 1% |
| Thyroid Gland Carcinoma | 2/45 4% | 9/1592 1% |
| Hepatocellular Carcinoma | 0/46 0% | 15/2210 1% |
| Head and Neck Carcinoma | 1/85 1% | 9/1574 1% |
| Kidney Carcinoma | 0/85 0% | 10/1862 1% |
| Rhabdomyosarcoma | 1/33 3% | 0/171 0% |
| Osteosarcoma | 0/45 0% | 1/166 1% |
| Burkitts Lymphoma | 1/32 3% | 0/196 0% |
| Non-Cancerous | 0/104 0% | 4/830 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 9/2534 0% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 6/2550 0% |
Mutation Distribution
Where IL12RB2 is mutated · all tissues, split by cell line vs tissue
How many mutations in IL12RB2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,335 mutations in IL12RB2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|